Needham Maintains Buy on Boston Scientific, Raises Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reaffirmed a Buy rating on Boston Scientific (NYSE:BSX) and increased the price target from $60 to $71.
February 01, 2024 | 10:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has maintained a Buy rating on Boston Scientific and raised the price target from $60 to $71, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a bullish outlook on the stock, suggesting that the company's fundamentals or growth prospects have improved. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100